Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Weissman Website

Allan M. Weissman, M.D.

Selected Publications
1)  Ding W, Li C, Hu T, Graves-Deal R, Fotia AB, Weissman AM, Coffey RJ.
EGF receptor-independent action of TGF-alpha protects Naked2 from AO7-mediated ubiquitylation and proteasomal degradation.
Proc. Natl. Acad. Sci. U.S.A. 105: 13433-8, 2008. [Journal]
2)  Kitagaki J, Agama KK, Pommier Y, Yang Y, Weissman AM.
Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2.
Mol. Cancer Ther. 7: 2445-54, 2008. [Journal]
3)  Weissman AM, Yang Y, Kitagaki J, Saiela CA, Beutler JA, O' Keefe B.
Inhibiting Hdm2 and ubiquitin-activating enzyme: targeting the ubiquitin conjugating system in cancer. In: Ernst Schering Res Found Workshop. Volume ?.
2008. In Press. [Book Chapter]
4)  Shenoy SK, Xiao K, Venkataramanan V, Snyder PM, Freedman NJ, Weissman AM.
Nedd4 Mediates Agonist-dependent Ubiquitination, Lysosomal Targeting, and Degradation of the {beta}2-Adrenergic Receptor.
J. Biol. Chem. 283: 22166-76, 2008. [Journal]
5)  Weissman AM.
How much REST is enough?.
Cancer Cell. 13: 381-3, 2008. [Journal]
6)  Cohen MM, Leboucher GP, Livnat-Levanon N, Glickman MH, Weissman AM.
Ubiquitin-Proteasome-dependent Degradation of a Mitofusin, a Critical Regulator of Mitochondrial Fusion.
Mol. Biol. Cell. 19: 2457-64, 2008. [Journal]
7)  Sasiela CA, Stewart DH, Kitagaki J, Safiran YJ, Yang Y, Weissman AM, Oberoi P, Davydov IV, Goncharova E, Beutler JA, McMahon JB, O'Keefe BR.
Identification of inhibitors for MDM2 ubiquitin ligase activity from natural product extracts by a novel high-throughput electrochemiluminescent screen.
Journal of biomolecular screening : the official journal of the Society for Biomolecular Screening. 13: 229-37, 2008. [Journal]
8)  Kostova Z, Tsai YC, Weissman AM.
Ubiquitin ligases, critical mediators of endoplasmic reticulum-associated degradation.
Semin Cell Dev Biol. 2007. [Journal]
9)  Tsai YC, Mendoza A, Mariano JM, Zhou M, Kostova Z, Chen B, Veenstra T, Hewitt SM, Helman LJ, Khanna C, Weissman AM.
The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation.
Nat. Med. 13: 1504-9, 2007. [Journal]
10)  Yang Y, Kitagaki J, Dai RM, Tsai YC, Lorick KL, Ludwig RL, Pierre SA, Jensen JP, Davydov IV, Oberoi P, Li CC, Kenten JH, Beutler JA, Vousden KH, Weissman AM.
Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics.
Cancer Res. 67: 9472-81, 2007. [Journal]
11)  Brauweiler A, Lorick KL, Lee JP, Tsai YC, Chan D, Weissman AM, Drabkin HA, Gemmill RM.
RING-dependent tumor suppression and G2/M arrest induced by the TRC8 hereditary kidney cancer gene.
Oncogene. 26: 2263-71, 2007. [Journal]
12)  Mani A, Oh AS, Bowden ET, Lahusen T, Lorick KL, Weissman AM, Schlegel R, Wellstein A, Riegel AT.
E6AP Mediates Regulated Proteasomal Degradation of the Nuclear Receptor Coactivator Amplified in Breast Cancer 1 in Immortalized Cells.
Cancer Res. 66: 8680-6, 2006. [Journal]
13)  Lorick KL, Yang Y, Jensen JP, Iwai K, Weissman AM.
Studies of the ubiquitin proteasome system.
Current protocols in cell biology / editorial board, Juan S. Bonifacino ... [et al.]. Chapter 15: Unit 15.9, 2006. [Journal]
14)  Lee S, Tsai YC, Mattera R, Smith WJ, Kostelansky MS, Weissman AM, Bonifacino JS, Hurley JH.
Structural basis for ubiquitin recognition and autoubiquitination by Rabex-5.
Nat. Struct. Mol. Biol. 13: 264-71, 2006. [Journal]
15)  Chen B, Mariano J, Tsai YC, Chan AH, Cohen M, Weissman AM.
The activity of a human endoplasmic reticulum-associated degradation E3, gp78, requires its Cue domain, RING finger, and an E2-binding site.
Proc. Natl. Acad. Sci. U.S.A. 103: 341-6, 2006. [Journal]
16)  Mattera R, Tsai YC, Weissman AM, Bonifacino JS.
The Rab5 guanine nucleotide exchange factor Rabex-5 binds ubiquitin (Ub) and functions as a Ub ligase through an atypical Ub-interacting motif and a zinc finger domain.
J. Biol. Chem. 281: 6874-83, 2006. [Journal]
17)  Yang Y, Lorick KL, Jensen JP, Weissman AM.
Expression and evaluation of RING finger proteins.
Meth. Enzymol. 398: 103-12, 2005. [Journal]
18)  Lorick KL, Jensen JP, Weissman AM.
Expression, purification, and properties of the Ubc4/5 family of E2 enzymes.
Meth. Enzymol. 398: 54-68, 2005. [Journal]
19)  Lorick KL, Tsai YC, Yang Y, Weissman AM. Mayer J, Ciechanover A, Rechsteiner M, eds.
RING fingers and relatives: determinators of protein fate. In: Protein Degradation. Volume 1.
Zurich: Wiley-VCH; 2005. p. 44-101 [Book Chapter]
20)  Megumi Y, Miyauchi Y, Sakurai H, Nobeyama H, Lorick K, Nakamura E, Chiba T, Tanaka K, Weissman AM, Kirisako T, Ogawa O, Iwai K.
Multiple roles of Rbx1 in the VBC-Cul2 ubiquitin ligase complex.
Genes Cells. 10: 679-91, 2005. [Journal]
21)  Yang Y, Ludwig RL, Jensen JP, Pierre SA, Medaglia MV, Davydov IV, Safiran YJ, Oberoi P, Kenten JH, Phillips AC, Weissman AM, Vousden KH.
Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells.
Cancer Cell. 7: 547-59, 2005. [Journal]
22)  Davydov IV, Woods D, Safiran YJ, Oberoi P, Fearnhead HO, Fang S, Jensen JP, Weissman AM, Kenten JH, Vousden KH.
Assay for ubiquitin ligase activity: high-throughput screen for inhibitors of HDM2.
J Biomol Screen. 9: 695-703, 2004. [Journal]
23)  Yang Y, Li CC, Weissman AM.
Regulating the p53 system through ubiquitination.
Oncogene. 23: 2096-106, 2004. [Journal]
24)  Häkli M, Lorick KL, Weissman AM, Jänne OA, Palvimo JJ.
Transcriptional coregulator SNURF (RNF4) possesses ubiquitin E3 ligase activity.
FEBS Lett. 560: 56-62, 2004. [Journal]
25)  Plafker SM, Plafker KS, Weissman AM, Macara IG.
Ubiquitin charging of human class III ubiquitin-conjugating enzymes triggers their nuclear import.
J Cell Biol. 167: 649-59, 2004. [Journal]
26)  Fang S, Weissman AM.
A field guide to ubiquitylation.
Cell Mol Life Sci. 61: 1546-61, 2004. [Journal]
27)  Wu PY, Hanlon M, Eddins M, Tsui C, Rogers RS, Jensen JP, Matunis MJ, Weisman AM, Weissman AM, Wolberger CP, Pickart CM.
A conserved catalytic residue in the ubiquitin-conjugating enzyme family.
EMBO J. 22: 5241-50, 2003. [Journal]
28)  Weissman AM.
Solubilization of lymphocytes.
Current protocols in immunology / edited by John E. Coligan ... [et al.]. Chapter 8: Unit 8.1A, 2003. [Journal]
29)  Magnifico A, Ettenberg S, Yang C, Mariano J, Tiwari S, Fang S, Lipkowitz S, Weissman AM.
WW domain HECT E3s target Cbl RING finger E3s for proteasomal degradation.
J Biol Chem. 278: 43169-77, 2003. [Journal]
30)  Xu L, Yang L, Moitra PK, Hashimoto K, Rallabhandi P, Kaul S, Meroni G, Jensen JP, Weissman AM, D'Arpa P.
BTBD1 and BTBD2 colocalize to cytoplasmic bodies with the RBCC/tripartite motif protein, TRIM5delta.
Exp Cell Res. 288: 84-93, 2003. [Journal]
31)  Webster JM, Tiwari S, Weissman AM, Wojcikiewicz RJ.
Inositol 1,4,5-trisphosphate receptor ubiquitination is mediated by mammalian Ubc7, a component of the endoplasmic reticulum-associated degradation pathway, and is inhibited by chelation of intracellular Zn2+.
J Biol Chem. 278: 38238-46, 2003. [Journal]
32)  Doong H, Rizzo K, Fang S, Kulpa V, Weissman AM, Kohn EC.
CAIR-1/BAG-3 abrogates heat shock protein-70 chaperone complex-mediated protein degradation: accumulation of poly-ubiquitinated Hsp90 client proteins.
J Biol Chem. 278: 28490-500, 2003. [Journal]
33)  Liang JS, Kim T, Fang S, Yamaguchi J, Weissman AM, Fisher EA, Ginsberg HN.
Overexpression of the tumor autocrine motility factor receptor Gp78, a ubiquitin protein ligase, results in increased ubiquitinylation and decreased secretion of apolipoprotein B100 in HepG2 cells.
J Biol Chem. 278: 23984-8, 2003. [Journal]
34)  Itoh M, Kim CH, Palardy G, Oda T, Jiang YJ, Maust D, Yeo SY, Lorick K, Wright GJ, Ariza-McNaughton L, Weissman AM, Lewis J, Chandrasekharappa SC, Chitnis AB.
Mind bomb is a ubiquitin ligase that is essential for efficient activation of Notch signaling by Delta.
Dev Cell. 4: 67-82, 2003. [Journal]
35)  Fang S, Lorick KL, Jensen JP, Weissman AM.
RING finger ubiquitin protein ligases: implications for tumorigenesis, metastasis and for molecular targets in cancer.
Semin Cancer Biol. 13: 5-14, 2003. [Journal]
36)  Xie Q, Guo HS, Dallman G, Fang S, Weissman AM, Chua NH.
SINAT5 promotes ubiquitin-related degradation of NAC1 to attenuate auxin signals.
Nature. 419: 167-70, 2002. [Journal]
37)  Murillas R, Simms KS, Hatakeyama S, Weissman AM, Kuehn MR.
Identification of developmentally expressed proteins that functionally interact with Nedd4 ubiquitin ligase.
J Biol Chem. 277: 2897-907, 2002. [Journal]
38)  Fang S, Ferrone M, Yang C, Jensen JP, Tiwari S, Weissman AM.
The tumor autocrine motility factor receptor, gp78, is a ubiquitin protein ligase implicated in degradation from the endoplasmic reticulum.
Proc Natl Acad Sci U S A. 98: 14422-7, 2001. [Journal]
39)  Ettenberg SA, Magnifico A, Cuello M, Nau MM, Rubinstein YR, Yarden Y, Weissman AM, Lipkowitz S.
Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex.
J Biol Chem. 276: 27677-84, 2001. [Journal]
40)  Tiwari S, Weissman AM.
Endoplasmic reticulum (ER)-associated degradation of T cell receptor subunits. Involvement of ER-associated ubiquitin-conjugating enzymes (E2s).
J Biol Chem. 276: 16193-200, 2001. [Journal]
41)  Weissman AM.
Themes and variations on ubiquitylation.
Nat Rev Mol Cell Biol. 2: 169-78, 2001. [Journal]
42)  Joazeiro CA, Weissman AM.
RING finger proteins: mediators of ubiquitin ligase activity.
Cell. 102: 549-52, 2000. [Journal]
43)  Weissman AM.
Detecting ubiquitinated T-cell antigen receptor subunits by immunoblotting.
Methods Mol Biol. 134: 283-7, 2000. [Journal]
44)  Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD.
Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli.
Science. 288: 874-7, 2000. [Journal]
45)  Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM.
Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53.
J Biol Chem. 275: 8945-51, 2000. [Journal]
46)  Lorick KL, Jensen JP, Fang S, Ong AM, Hatakeyama S, Weissman AM.
RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination.
Proc Natl Acad Sci U S A. 96: 11364-9, 1999. [Journal]
47)  Iwai K, Drake SK, Wehr NB, Weissman AM, LaVaute T, Minato N, Klausner RD, Levine RL, Rouault TA.
Iron-dependent oxidation, ubiquitination, and degradation of iron regulatory protein 2: implications for degradation of oxidized proteins.
Proc. Natl. Acad. Sci. U.S.A. 95: 4924-8, 1998. [Journal]
48)  Yang M, Omura S, Bonifacino JS, Weissman AM.
Novel aspects of degradation of T cell receptor subunits from the endoplasmic reticulum (ER) in T cells: importance of oligosaccharide processing, ubiquitination, and proteasome-dependent removal from ER membranes.
J. Exp. Med. 187: 835-46, 1998. [Journal]
49)  Rellahan BL, Jensen JP, Howcroft TK, Singer DS, Bonvini E, Weissman AM.
Elf-1 regulates basal expression from the T cell antigen receptor zeta-chain gene promoter.
J. Immunol. 160: 2794-801, 1998. [Journal]
50)  Bonifacino JS, Weissman AM.
Ubiquitin and the control of protein fate in the secretory and endocytic pathways.
Annu. Rev. Cell Dev. Biol. 14: 19-57, 1998. [Journal]
51)  D'Oro U, Vacchio MS, Weissman AM, Ashwell JD.
Activation of the Lck tyrosine kinase targets cell surface T cell antigen receptors for lysosomal degradation.
Immunity. 7: 619-28, 1997. [Journal]
52)  Orford K, Crockett C, Jensen JP, Weissman AM, Byers SW.
Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin.
J. Biol. Chem. 272: 24735-8, 1997. [Journal]
53)  Hatakeyama S, Jensen JP, Weissman AM.
Subcellular localization and ubiquitin-conjugating enzyme (E2) interactions of mammalian HECT family ubiquitin protein ligases.
J. Biol. Chem. 272: 15085-92, 1997. [Journal]
54)  Weissman AM.
Regulating protein degradation by ubiquitination.
Immunol. Today. 18: 189-98, 1997. [Journal]
55)  Yang M, Ellenberg J, Bonifacino JS, Weissman AM.
The transmembrane domain of a carboxyl-terminal anchored protein determines localization to the endoplasmic reticulum.
J. Biol. Chem. 272: 1970-5, 1997. [Journal]
56)  Cenciarelli C, Wilhelm KG, Guo A, Weissman AM.
T cell antigen receptor ubiquitination is a consequence of receptor-mediated tyrosine kinase activation.
J. Biol. Chem. 271: 8709-13, 1996. [Journal]
57)  Jensen JP, Bates PW, Yang M, Vierstra RD, Weissman AM.
Identification of a family of closely related human ubiquitin conjugating enzymes.
J. Biol. Chem. 270: 30408-14, 1995. [Journal]
58)  Niklinska BB, Hou D, June C, Weissman AM, Ashwell JD.
CD45 tyrosine phosphatase activity and membrane anchoring are required for T-cell antigen receptor signaling.
Mol. Cell. Biol. 14: 8078-84, 1994. [Journal]
59)  Rellahan BL, Jensen JP, Weissman AM.
Transcriptional regulation of the T cell antigen receptor zeta subunit: identification of a tissue-restricted promoter.
J. Exp. Med. 180: 1529-34, 1994. [Journal]
60)  Hou D, Cenciarelli C, Jensen JP, Nguygen HB, Weissman AM.
Activation-dependent ubiquitination of a T cell antigen receptor subunit on multiple intracellular lysines.
J. Biol. Chem. 269: 14244-7, 1994. [Journal]
61)  Weissman AM.
The T-cell antigen receptor: a multisubunit signaling complex.
Chem. Immunol. 59: 1-18, 1994. [Journal]
62)  Gotlieb WH, Bristol LA, Weissman AM, Durum SK, Takács L.
Upregulation of T cell receptor gamma chain transcription by interleukin-2.
Cell. Immunol. 151: 345-55, 1993. [Journal]
63)  Volarević S, Niklinska BB, Burns CM, June CH, Weissman AM, Ashwell JD.
Regulation of TCR signaling by CD45 lacking transmembrane and extracellular domains.
Science. 260: 541-4, 1993. [Journal]
64)  Jensen JP, Cenciarelli C, Hou D, Rellahan BL, Dean M, Weissman AM.
T cell antigen receptor-eta subunit. Low levels of expression and limited cross-species conservation.
J. Immunol. 150: 122-30, 1993. [Journal]
65)  Kosugi A, Weissman AM, Ogata M, Hamaoka T, Fujiwara H.
Instability of assembled T-cell receptor complex that is associated with rapid degradation of zeta chains in immature CD4+CD8+ thymocytes.
Proc. Natl. Acad. Sci. U.S.A. 89: 9494-8, 1992. [Journal]
66)  Cenciarelli C, Hou D, Hsu KC, Rellahan BL, Wiest DL, Smith HT, Fried VA, Weissman AM.
Activation-induced ubiquitination of the T cell antigen receptor.
Science. 257: 795-7, 1992. [Journal]
67)  Cenciarelli C, Hohman RJ, Atkinson TP, Gusovsky F, Weissman AM.
Evidence for GTP-binding protein involvement in the tyrosine phosphorylation of the T cell receptor zeta chain.
J. Biol. Chem. 267: 14527-30, 1992. [Journal]
68)  Frank SJ, Cenciarelli C, Niklinska BB, Letourneur F, Ashwell JD, Weissman AM.
Mutagenesis of T cell antigen receptor zeta chain tyrosine residues. Effects on tyrosine phosphorylation and lymphokine production.
J. Biol. Chem. 267: 13656-60, 1992. [Journal]
69)  Jensen JP, Hou D, Ramsburg M, Taylor A, Dean M, Weissman AM.
Organization of the human T cell receptor zeta/eta gene and its genetic linkage to the Fc gamma RII-Fc gamma RIII gene cluster.
J. Immunol. 148: 2563-71, 1992. [Journal]
70)  Gotlieb WH, Takacs L, Finch LR, Kopp W, Weissman AM, Durum SK.
CD8 gamma delta cells: presence in the adult rat thymus and generation in vitro from CD4-/CD8- thymocytes in the presence of interleukin 2.
Cytokine. 3: 598-608, 1991. [Journal]
71)  Zacharchuk CM, Merćep M, June CH, Weissman AM, Ashwell JD.
Variations in thymocyte susceptibility to clonal deletion during ontogeny. Implications for neonatal tolerance.
J. Immunol. 147: 460-5, 1991. [Journal]
72)  O'Shea JJ, Weissman AM, Kennedy IC, Ortaldo JR.
Engagement of the natural killer cell IgG Fc receptor results in tyrosine phosphorylation of the zeta chain.
Proc. Natl. Acad. Sci. U.S.A. 88: 350-4, 1991. [Journal]
73)  Weissman A, Vousden K, Jensen J, Yang Y, Fang S, Woods D, Kenten J, Davydov L, Safiran Y, Oberoi P, inventor; DHHS, assignee.
Deazaflavin Compounds and Methods of Use Thereof.
Patent Pending Application No. 10/545,547. Pending [Patent]
74)  Weissman A, Mariano J, Chen B, Tsai YC, inventor; DHHS, assignee.
The UBE2G2 Binding Domain in the Ubiquitin Ligase GP78 and Methods of Use Thereof.
Patent Pending Application No. 60/583,263. Pending [Patent]
75)  Weissman A, Yang Y, inventor; DHHS, assignee.
Inhibitors of the Ubiquitin E1.
Patent Pending Application No. 60/738,242. Pending [Patent]

This page was last updated on 12/1/2008.